Baader Bank Aktiengesellschaft Invests $234,000 in Insulet Co. (NASDAQ:PODD)

Baader Bank Aktiengesellschaft acquired a new stake in Insulet Co. (NASDAQ:PODD) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 898 shares of the medical instruments supplier’s stock, valued at approximately $234,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Baillie Gifford & Co. grew its position in shares of Insulet by 20.7% in the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier’s stock valued at $529,669,000 after purchasing an additional 389,639 shares during the last quarter. Mizuho Securities USA LLC grew its holdings in Insulet by 5,928.1% during the 3rd quarter. Mizuho Securities USA LLC now owns 325,821 shares of the medical instruments supplier’s stock valued at $75,835,000 after buying an additional 320,416 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in Insulet by 43.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier’s stock worth $148,091,000 after buying an additional 193,839 shares in the last quarter. Westfield Capital Management Co. LP raised its holdings in shares of Insulet by 27.6% in the third quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier’s stock worth $175,697,000 after acquiring an additional 163,388 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new stake in shares of Insulet in the third quarter valued at $16,342,000.

Insulet Price Performance

PODD opened at $278.38 on Friday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $286.39. The company has a 50 day moving average of $268.69 and a two-hundred day moving average of $237.96. The company has a market cap of $19.53 billion, a P/E ratio of 47.67, a P/E/G ratio of 3.48 and a beta of 1.22. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $0.90 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.13. Insulet had a net margin of 21.22% and a return on equity of 27.98%. The firm had revenue of $543.90 million during the quarter, compared to analysts’ expectations of $518.50 million. During the same period in the prior year, the company earned $0.71 EPS. On average, analysts expect that Insulet Co. will post 3.22 earnings per share for the current year.

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of Insulet stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at $3,187,240. The trade was a 52.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Lauren Budden sold 915 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the transaction, the chief accounting officer now directly owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Canaccord Genuity Group boosted their target price on shares of Insulet from $269.00 to $304.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Raymond James upped their price objective on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Wells Fargo & Company lifted their target price on shares of Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 11th. BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Finally, Barclays lifted their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $272.81.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.